Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4367933 | 0.85 | GABRA1 (0.45) | KMT2A | |
| SCHEMBL15820759 | 0.80 | SLC6A2 (0.50) | KMT2ASLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL2857779 | 0.77 | SLC6A2 (0.61) | KMT2ASLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL28002408 | 0.77 | SLC6A2 (0.47) | KMT2ASLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL6699017 | 0.76 | SLC6A2 (0.42) | KMT2ASLC6A2TAAR1SLC6A4SLC6A3 | |
| SCHEMBL26620310 | 0.75 | ALDH1A1 (0.34) | TAAR1 | |
| SCHEMBL3415124 | 0.75 | APOBEC3G (0.39) | — | |
| SCHEMBL28368759 | 0.74 | CYP2D6 (0.42) | ADRA2A | |
| SCHEMBL14655700 | 0.73 | KMT2A (0.64) | KMT2ATAAR1HTR2A | |
| SCHEMBL30249073 | 0.73 | KMT2A (0.64) | KMT2ATAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476195-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2004-11-17 | — | — | EP | claimed |
| WO-2002005851-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | claimed |
| US-20250340672-A1 | VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | REGENERON PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| US-20240124613-A1 | VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | REGENERON PHARMA (US) | 2024-04-18 | — | — | US | disclosed |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-03-01 | — | — | US | disclosed |
| EP-2938608-B1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD BURNHAM MED RES INST (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200377618-A1 | VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | REGENERON PHARMACEUTICALS, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-10787522-B2 | VL antigen binding proteins exhibiting distinct binding characteristics | REGENERON PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-10584103-B2 | Small molecule agonists of neurotensin receptor 1 | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-03-10 | — | — | US | disclosed |
| EP-3119811-B1 | VL ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS | REGENERON PHARMA (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20120301422-A1 | ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS AND OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS AND TRANSPORTATION OF NUCLEIC ACID SUBSTANCES | NORTH WEST UNIVERSITY (ZA) | 2012-11-29 | — | — | US | disclosed |
| US-7564027-B2 | Adsorption, detection and identification of components of ambient air with desorption/ionization on silicon mass spectrometry (DIOS-MS) | WATERS INVESTMENTS LIMITED (US) | 2009-07-21 | — | — | US | disclosed |
| US-20070087446-A1 | Aromatic phosphonium salts and their use as labeling reagents in mass spectrometry analysis | WATERS INVESTMENTS LIMITED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070023627-A1 | Adsorption, detection and identification of components of ambient air with desorption/ionization on silicon mass spectrometry (dios-ms) | WATERS INVESTMENTS LIMITED (DE) | 2007-02-01 | — | — | US | disclosed |
| CN-1896098-A | Buthotoxin polypeptide and its use | ZHAO ENCHENG (CN) | 2007-01-17 | — | — | CN | disclosed |
| WO-2005029003-A2 | IDENTIFICATION OF AIR COMPONENTS WITH SILICON MASS SPECTROMETRY | WATERS INVESTMENTS LIMITED (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1476195-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004092707-A2 | AROMATIC PHOSPHONIUM SALTS AND THEIR USE AS LABELING REAGENTS MASS SPECTROMETRY ANALYSIS | WATERS INVESTMENTS LIMITED (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2002005851-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584103-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | KMT2A 4362/4885SLC6A2 322/4885TAAR1 46/4885 |
| US-11261164-B2 | Small molecule agonists of neurotensin receptor 1 | NTSR1, NTSR2, VIPR1 | KMT2A 4362/4885SLC6A2 322/4885TAAR1 46/4885 |
| US-20120301422-A1 | ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS AND OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS AND TRANSPORTATION OF NUCLEIC ACID SUBSTANCES | HRH2, HRH4, CNR2 | KMT2A 3966/4885SLC6A2 3267/4885TAAR1 953/4885 |
| US-20200354324-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | KMT2A 4362/4885SLC6A2 322/4885TAAR1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.